NASDAQ$ACLX
Arcellx Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Arcellx reported financial results and business highlights for Q3 2024.
Arcellx reported collaboration revenue of $26.0 million for the third quarter of 2024, an increase of $11.0 million compared to the same period in 2023. The company's cash, cash equivalents, and marketable securities totaled $676.7 million as of September 30, 2024, which is expected to fund operations into 2027. Net losses for the quarter were $25.9 million.
- ASH abstracts for Phase 1 and iMMagine-1 studies of anito-cel in relapsed/refractory multiple myeloma showed durability and manageable safety.
- Phase 1 study of anito-cel demonstrated a 30.2-month median progression-free survival with a median follow-up of 38.1 months.
- Preliminary results from the iMMagine-1 Phase 2 study showed a 95% ORR and 62% CR/sCR at a median follow-up of 10.3 months.
- First patients dosed in iMMagine-3 study, manufactured by Kite, with turnaround time in line with Kite’s commercial products.
Headline financials
Revenue & EPS history
Arcellx · Revenue · Quarterly
$26M
Forward guidance
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
+2.2%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+24.9%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+16.0%
Q2 2024
Best reaction
-4.8%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.2% | -0.1% | +0.2% | |
| Q3 2025 | -1.9% | +2.2% | -21.1% | |
| Q2 2025 | -0.9% | -0.2% | +2.1% | |
| Q1 2025 | -0.2% | +10.9% | +9.0% | |
| Q4 2024 | +2.0% | +1.2% | -19.9% | |
| Q3 2024 | +10.8% | +8.1% | -9.1% | |
| Q2 2024 | +16.0% | +19.1% | +40.0% | |
| Q1 2024 | -4.8% | -3.1% | -2.8% | |
| Q4 2023 | -2.7% | +0.4% | +2.9% | |
| Q3 2023 | +4.3% | +21.3% | +11.0% | |
| Q2 2023 | +6.7% | +3.3% | -0.7% | |
| Q1 2023 | +2.8% | -4.5% | -3.7% | |
| Q4 2022 | +0.9% | -2.9% | +41.1% | |
| Q3 2022 | -2.8% | -4.9% | +47.5% | |
| Q3 2021 | -2.8% | -4.9% | +47.5% | |
| Q2 2022 | +8.4% | -4.1% | +10.5% | |
| Q1 2022 | +0.2% | -15.5% | +174.8% | |
| Q1 2021 | +0.2% | -15.5% | +174.8% | |
| Q4 2021 | +5.9% | -8.7% | -30.2% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro